A phase 3 trial of a higher-dose CagriSema formulation at 2.4/7.2 mg is planned for initiation in the second half of 2026, and the REDEFINE 11 trial, exploring CagriSemas full weight-loss potential, is expected to report data in the first half of 2027
This combination therapy addresses multiple pathways, making it a robust solution for patients with type 2 diabetes and obesity
The capsule format enables dissolution studies, bioavailability research, and comparison with injectable formulations under controlled experimental conditions
At checkout, choose from Affirm (flexible monthly plans), Afterpay (interest-free Pay-in-4), Zelle (direct bank transfer), credit or debit card, Apple Pay, or Google Pay